CN101428006A - 微粒体组合物及其生产方法 - Google Patents

微粒体组合物及其生产方法 Download PDF

Info

Publication number
CN101428006A
CN101428006A CNA2008101750512A CN200810175051A CN101428006A CN 101428006 A CN101428006 A CN 101428006A CN A2008101750512 A CNA2008101750512 A CN A2008101750512A CN 200810175051 A CN200810175051 A CN 200810175051A CN 101428006 A CN101428006 A CN 101428006A
Authority
CN
China
Prior art keywords
microsome
compositions
detergent
antigen
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2008101750512A
Other languages
English (en)
Chinese (zh)
Inventor
J·-H·方
M·辛格
D·奥黑根
M·霍拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of CN101428006A publication Critical patent/CN101428006A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA2008101750512A 2000-09-28 2001-09-28 微粒体组合物及其生产方法 Pending CN101428006A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23607700P 2000-09-28 2000-09-28
US60/236,077 2000-09-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA018165575A Division CN1535140A (zh) 2000-09-28 2001-09-28 微粒体组合物及其生产方法

Publications (1)

Publication Number Publication Date
CN101428006A true CN101428006A (zh) 2009-05-13

Family

ID=22888043

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2008101750512A Pending CN101428006A (zh) 2000-09-28 2001-09-28 微粒体组合物及其生产方法
CNA018165575A Pending CN1535140A (zh) 2000-09-28 2001-09-28 微粒体组合物及其生产方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA018165575A Pending CN1535140A (zh) 2000-09-28 2001-09-28 微粒体组合物及其生产方法

Country Status (14)

Country Link
US (2) US6753015B2 (enExample)
EP (1) EP1322292B1 (enExample)
JP (2) JP2004509914A (enExample)
CN (2) CN101428006A (enExample)
AT (1) ATE350015T1 (enExample)
AU (2) AU9489801A (enExample)
BR (1) BR0114304A (enExample)
CA (1) CA2420621C (enExample)
DE (1) DE60125795T2 (enExample)
ES (1) ES2278786T3 (enExample)
MX (1) MXPA03002643A (enExample)
RU (1) RU2257198C2 (enExample)
WO (1) WO2002026212A2 (enExample)
ZA (1) ZA200301743B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
ES2195317T3 (es) * 1997-01-30 2003-12-01 Chiron Corp Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias.
AU2457100A (en) * 1999-02-26 2000-09-14 Chiron S.P.A. Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1240331B1 (en) * 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001051500A1 (en) 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US20030138453A1 (en) * 2000-09-28 2003-07-24 O'hagan Derek Microparticles for delivery of heterologous nucleic acids
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AU2002322358B2 (en) * 2001-06-29 2009-06-18 Novartis Vaccines And Diagnostics, Inc. HCV E1E2 vaccine compositions
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
JP4646516B2 (ja) * 2002-02-20 2011-03-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着したポリペプチド含有分子を有する微粒子
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US20040115254A1 (en) * 2002-09-06 2004-06-17 Genteric, Inc. Microcapsules and methods of use
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
WO2004032860A2 (en) 2002-10-07 2004-04-22 Chiron Corporation Hiv vaccine formulations
CA2506318C (en) 2002-11-15 2011-07-12 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2263687B1 (en) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
US20050191358A1 (en) * 2003-01-14 2005-09-01 Derek O' Hagan Microparticles with adsorbed polynucleotide-containing species
GB0300881D0 (en) * 2003-01-15 2003-02-12 Secr Defence Therapeutic treatment
AU2004224746B2 (en) * 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
WO2004096136A2 (en) * 2003-04-25 2004-11-11 Chiron Corporation Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
GB2407500A (en) * 2003-11-03 2005-05-04 Ist Superiore Sanita Use of microparticles for antigen delivery
US7682009B1 (en) * 2004-06-01 2010-03-23 Sliwa Jr John W Cooling, condensation and freezing of atmospheric water or of a microfluidic working-material in or on microfluidic devices
AU2005334819B2 (en) * 2004-11-15 2011-11-24 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant
JP2006169336A (ja) * 2004-12-15 2006-06-29 Nissan Motor Co Ltd 情報化核酸含有透明樹脂組成物
JP2006169337A (ja) * 2004-12-15 2006-06-29 Nissan Motor Co Ltd 不透明樹脂組成物
BRPI0614254A2 (pt) * 2005-08-02 2011-03-15 Novartis Vaccines & Diagnostic redução de interferência entre adjuvantes contendo óleo e antìgenos contendo tensoativos
US9393215B2 (en) * 2005-12-02 2016-07-19 Novartis Ag Nanoparticles for use in immunogenic compositions
RU2327170C2 (ru) * 2006-02-27 2008-06-20 Закрытое акционерное общество "ДиТест" Способ комплексной диагностики вирусного гепатита в, вирусного гепатита с, вич-инфекции и сифилиса
RU2326655C1 (ru) * 2006-11-09 2008-06-20 Федеральное государственное учреждение "48 Центральный научно-исследовательский институт Министерства обороны Российской Федерации" Способ инкапсулирования белоксодержащих веществ в микросферы из сополимера полилактид-полигликолид
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
WO2009134769A1 (en) * 2008-04-28 2009-11-05 Novartis Ag Nanoparticles for use in pharmaceutical compositions
RU2392668C1 (ru) * 2008-12-15 2010-06-20 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" Способ индукции антипролиферативного, цитотоксического эффекта в опухолевых клетках линейных и свежевыделенных культур
EP2440185B1 (en) 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
RU2413311C1 (ru) * 2009-07-29 2011-02-27 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" Способ индукции антипролиферативного действия в эксперименте
EP2525815B1 (en) * 2010-01-24 2015-02-25 Novartis AG Irradiated biodegradable polymer microparticles
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2555798B1 (en) * 2010-04-09 2016-06-22 Reef Pharmaceuticals Pty Ltd Methods and compositions for inhibiting hiv transmission
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
US20140105970A1 (en) * 2011-12-01 2014-04-17 Flow Pharma, Inc. Adjuvant and antigen particle formulation
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
CA2932532C (en) 2012-12-04 2021-06-22 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
JP6671300B2 (ja) * 2014-05-27 2020-03-25 アーティフィシャル セル テクノロジーズ インコーポレイテッド Ｔｆｆによる多層コーティング化コアの自動交互積層構築
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CN114617959A (zh) 2015-09-03 2022-06-14 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
BR112020000506A2 (pt) 2017-07-11 2020-07-14 Sustained Nano Systems Llc formulações farmacêuticas hipercomprimidas
EP3461857A1 (en) * 2017-09-28 2019-04-03 Helmholtz-Zentrum Geesthacht Zentrum für Material- und Küstenforschung GmbH Surface-functionalised polymeric object and method of its production
US12220486B2 (en) 2018-03-02 2025-02-11 Saint Joseph's University Polymer compositions for storage and release of polypeptides

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE634667A (enExample) 1962-07-11
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
PL174772B1 (pl) * 1993-01-06 1998-09-30 Kinerton Ltd Kompozycja farmaceutyczna zawierająca jonowy konjugat cząsteczkowy
DE69418699T2 (de) 1993-01-11 1999-09-30 Dana-Farber Cancer Institute, Boston Induktion der antworten zytotoxischer t-lymphozyten
GB9311454D0 (en) 1993-06-03 1993-07-21 Agricultural & Food Res Pharmaceutical compositions
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
ATE252894T1 (de) * 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
GB9514285D0 (en) 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery
JPH09255590A (ja) * 1996-03-21 1997-09-30 Japan Synthetic Rubber Co Ltd 徐放性薬剤
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
ES2301178T3 (es) 1996-04-05 2008-06-16 Novartis Vaccines & Diagnostic Vectores basados en alfavirus recombinantes con inhibicion reducida de la sintesis macromolecular celular.
GB9619002D0 (en) 1996-09-11 1996-10-23 Oxford Biosciences Ltd Particle delivery
US6491925B2 (en) * 1996-08-15 2002-12-10 Emory University Compositions and methods for cancer prophylaxis and/or treatment
US5842723A (en) 1996-11-25 1998-12-01 Burex Automotive America, Inc. Flexible connection arrangement for connecting a pipe of an exhaust system to an engine, especially in a motor vehicle
US5783567A (en) 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
ES2195317T3 (es) 1997-01-30 2003-12-01 Chiron Corp Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias.
WO2000006123A1 (en) * 1998-07-29 2000-02-10 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US5840970A (en) * 1997-10-03 1998-11-24 Eastman Chemical Company Process for the purification of naphthalenedicarboxylic acid
PT1042001E (pt) 1997-12-16 2002-09-30 Chiron Corp Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua
US6395253B2 (en) * 1998-04-23 2002-05-28 The Regents Of The University Of Michigan Microspheres containing condensed polyanionic bioactive agents and methods for their production
WO2000050006A2 (en) 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
US20020009466A1 (en) * 1999-08-31 2002-01-24 David J. Brayden Oral vaccine compositions
ES2411096T3 (es) * 1999-10-27 2013-07-04 Novartis Vaccines And Diagnostics, Inc. Activación de linfocitos T específicos contra el VHC
WO2001036599A1 (en) 1999-11-19 2001-05-25 Chiron Corporation Microparticle-based transfection and activation of dendritic cells
US20010046967A1 (en) * 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
WO2001081609A2 (en) 2000-03-22 2001-11-01 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems

Also Published As

Publication number Publication date
EP1322292B1 (en) 2007-01-03
US20040156913A1 (en) 2004-08-12
BR0114304A (pt) 2003-07-29
ES2278786T3 (es) 2007-08-16
US20020136776A1 (en) 2002-09-26
US6753015B2 (en) 2004-06-22
ATE350015T1 (de) 2007-01-15
WO2002026212A2 (en) 2002-04-04
AU2001294898B2 (en) 2006-02-02
AU9489801A (en) 2002-04-08
DE60125795D1 (de) 2007-02-15
CN1535140A (zh) 2004-10-06
DE60125795T2 (de) 2007-10-18
WO2002026212A3 (en) 2003-03-27
US7846479B2 (en) 2010-12-07
JP2004509914A (ja) 2004-04-02
ZA200301743B (en) 2004-10-04
RU2257198C2 (ru) 2005-07-27
JP2013147514A (ja) 2013-08-01
CA2420621A1 (en) 2002-04-04
CA2420621C (en) 2011-05-24
EP1322292A2 (en) 2003-07-02
MXPA03002643A (es) 2003-06-19

Similar Documents

Publication Publication Date Title
AU2001294898B2 (en) Microparticle compositions and methods for the manufacture thereof
CN1798548B (zh) 基于含吸附类毒素和含多糖抗原微粒体的免疫原性组合物
CN1468089B (zh) 用于传送异源核酸的微粒体
JP5832485B2 (ja) 吸着したポリペプチド含有分子を有する微粒子
EP1585542B1 (en) Immunogenic compositions containing phospholipid
AU2001294898A1 (en) Microparticle compositions and methods for the manufacture thereof
US20150072016A1 (en) Microparticles with adsorbed polynucleotide-containing species
PT1585542E (pt) Composições imunogénicas contendo fosfolípido
HK1087943B (en) Immunogenic compositions based on biodegradable microparticles comprising a diphtheria- and a tetanus toxoid

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090513